{"id":"adalimumab-new-formulation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to TNF-alpha, adalimumab prevents it from interacting with its receptor on cell surfaces, thereby reducing inflammation and immune system activation. This mechanism is thought to contribute to its therapeutic effects in various autoimmune diseases.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:12.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT01752855","phase":"PHASE2","title":"Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT01712178","phase":"PHASE2","title":"A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01502423","phase":"PHASE2","title":"A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":61},{"nctId":"NCT01561313","phase":"PHASE2","title":"Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-03","conditions":"Rheumatoid Arthritis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Adalimumab, new formulation","genericName":"Adalimumab, new formulation","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a TNF-alpha inhibitor, classified as an antibody and a drug that inhibits tumor necrosis factor. It is used to treat rheumatoid arthritis, with a new formulation being compared to the current formulation in clinical trials for pharmacokinetic, pharmacodynamic, and safety assessments.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}